Enfortumab vedotin in the previously treated advanced head and neck cancer (HNC) cohort of EV-202

被引：0
|
作者：
Swiecicki, Paul
Yilmaz, Emrullah
Rosenberg, Ari J.
Fujisawa, Takao
Bruce, Justine Yang
Meng, Changting
Wozniak, Michele
Wang, Lu
Gorla, Seema Rao
Geiger, Jessica Lyn
机构：
[1] Univ Michigan, Sch Med, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI USA
[2] Cleveland Clin, Cleveland, OH USA
[3] Univ Chicago, Hematol Oncol Sect, Dept Med, Chicago, IL USA
[4] Natl Canc Ctr East Hosp, Dept Head & Neck Med Oncol, Translat Res Support Off, Chiba, Japan
[5] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[6] Seagen Inc, Bothell, WA USA
[7] Astellas Pharma US Inc, Northbrook, IL USA
[8] Astellas Pharma Inc, Northbrook, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6017
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase II open-label study of enfortumab vedotin in patients with previously treated locally advanced, recurrent, or metastatic pancreatic adenocarcinoma (EPIC).
    Kasi, Anup
    Phadnis, Milind A.
    Al-Rajabi, Raed Moh'd Taiseer
    Baranda, Joaquina Celebre
    Li, Haoran
    Carroll, Erin
    Belcher, Cathey
    Bradbury, Shannon
    Collins, Zachary
    Sun, Weijing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS719 - TPS719
  • [42] Real-world use, dose intensity, and adherence to enfortumab vedotin (EV) in locally advanced or metastatic urothelial cancer (la/mUC)
    Tsingas, Konstantinos
    Parikh, Ravi Bharat
    Elsouda, Dina
    Mucha, Lisa
    Fuldeore, Rupali
    Hubbard, Rebecca A.
    Mamtani, Ronac
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] Increased risk of hyperglycemia in patients with advanced urothelial cancer treated with enfortumab vedotin: A systematic review and meta-analysis
    Cheng, Ryan
    Boparai, Montek
    Wu, Shenhong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus chemotherapy.
    Mamtani, Ronac
    Rosenberg, Jonathan E.
    Powles, Thomas
    Sonpavde, Guru P.
    Loriot, Yohann
    Duran, Ignacio
    Lee, Jae-Lyun
    Matsubara, Nobuaki
    Vulsteke, Christof
    Castellano, Daniel
    Sridhar, Srikala S.
    Pappot, Helle
    Valderrama, Begona P.
    Gurney, Howard
    Bedke, Jens
    Van der Heijden, Michiel Simon
    Wu, Chunzhang
    Hepp, Zsolt
    McKay, Caroline
    Petrylak, Daniel P.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [45] EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) plus pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)
    Powles, T. B.
    Van der Heijden, M. S.
    Gupta, S.
    Perez Valderrama, B.
    Galsky, M. D.
    Bedke, J.
    Kikuchi, E.
    Hoffman-Censits, J.
    Rey, J. P. Maroto
    Vulsteke, C.
    Iyer, G.
    Swami, U.
    Shin, S. J.
    Rodriguez-Vida, A.
    Wozniak, M.
    Moreno, B. Homet
    Lu, J.
    Yu, C.
    Hogdal, L.
    Loriot, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1137 - S1138
  • [46] Enfortumab vedotin (EV) in cisplatin-eligible and ineligible patients with advanced urothelial cancer (aUC): A single-center experience.
    Vlachou, Evangelia
    Johnson, Burles Avner
    Elias, Roy
    Hahn, Noah M.
    Mcconkey, David James
    Hoffman-Censits, Jean H.
    Hoffman-Censits, Jean H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 569 - 569
  • [47] INTENSIVE INDUCTION CHEMOTHERAPY (IND CT) FOR LOCALLY ADVANCED HEAD AND NECK-CANCER (HNC)
    VOKES, EE
    MORAN, WJ
    LESTER, EP
    SCHILSKY, RL
    BITRAN, JD
    SUTTON, HH
    HAGLE, ME
    SOLARSKI, AM
    KNAPP, BA
    WEICHSELBAUM, RR
    PANJE, WR
    CANCER DRUG DELIVERY, 1986, 3 (01): : 60 - 60
  • [48] Quality of life of metastatic urothelial cancer (mUC) patients treated with enfortumab vedotin (EV) following platinum-containing chemotherapy and a checkpoint inhibitor (CPI): Data from EV-201 cohort 1
    McGregor, B. A.
    O'Donnell, P. H.
    Balar, A.
    Petrylak, D. P.
    Rosenberg, J. E.
    Yu, E.
    Quinn, D. I.
    Shah, S. N.
    Pinelli, J.
    Hepp, Z.
    Galsky, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [49] EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
    Rosenberg, J. E.
    Powles, T.
    Sonpavde, G. P.
    Loriot, Y.
    Duran, I.
    Lee, J. -L.
    Matsubara, N.
    Vulsteke, C.
    Castellano, D.
    Mamtani, R.
    Wu, C.
    Matsangou, M.
    Campbell, M.
    Petrylak, D. P.
    ANNALS OF ONCOLOGY, 2023, 34 (11) : 1047 - 1054
  • [50] Locoregional Failure Patterns for Advanced Head and Neck Cancer (HNC) Treated Definitively by IMRT: The Impact of PET-CT on Treatment Planning
    de Andrade, R. S.
    Heron, D. E.
    Jain, S.
    McCoy, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S652 - S653
12345